The company said during a conference call following release of its Q1 2025 results that it purchases roughly 80 percent of ...

In one case a firm is alleged to have improperly billed the COVID-19 Uninsured Program while in the other a firm paid and received kickbacks for unnecessary genetic testing.

SSID Group said that the assets acquired in the deal will complement its gastric health portfolio and let it offer a broader range of tests to US labs.

A number of the Dutch firm's products have received certification under Europe's In Vitro Diagnostic Regulation recently.

NEW YORK – Roche announced on Wednesday that it has received CE marking for its Chest Pain Triage algorithm to help rule in and rule out heart attacks in the emergency department.

The project will use Akoya's PhenoCode Discovery IO60 Panel to look at matched pairs of immuno-oncology exceptional responders and hyper-progressors.

The company has completed its FDA submission for the system and inked a deal with UAE-based healthcare provider Burjeel Holdings to deploy the system in its facilities.

NEW YORK – Impacts from China's volume-based procurement program and other healthcare pricing reforms led to flat Q1 diagnostics revenues year over year for Roche, company executives said Thursday.

NEW YORK — Swiss healthcare firm Roche said Monday that it intends to invest $50 billion over the next five years into expanding its footprint in the US. According to Roche, the money will be used in ...

The firm also reported its Life Sciences segment revenues fell 4 percent in the quarter, while Diagnostics revenues decreased 3 percent.

The Australian precision diagnostics firm said it will use the money to support the launch of its proteomic tests in Australia and the US.

The company's investment in diagnostics firm Recipe is part of an effort to develop its DART mass spec tech for therapeutic drug monitoring and drugs of abuse testing.